

**Disclaimer:** The content below is for communication purpose only. Our company and its affiliates do not guarantee to anybody that the information below is complete and up-to-date. Our company and its affiliates do not accept any responsibility for any decision made as a result of relying on the information contained herein.

More Details on: [www.microport.com.cn](http://www.microport.com.cn)

Email: [ir@microport.com](mailto:ir@microport.com)


Tel (021) 38954600

Fax (021) 50801305

## MicroPort La Fenice® GnRH Infusion Pump Brought Light to Sterility Patients

MicroPort La Fenice® GnRH Infusion Pump, the first pulsatile GnRH infusion pump in China, has brought light to sterility patients.

In recent years, the rate of infertility has risen to 12.5% in China, among which are suffered from Idiopathic Hypogonadotropic Hypogonadism (IHH). IHH, also known as Kallmann Syndrome, is a genetic disorder marked by anosmia and hypogonadism. Abnormalities in various genes may cause a defect in the hypothalamus, causing a deficiency of gonadotropin-releasing hormone (GnRH). This in turn causes deficiency in Follicle-Stimulating Hormone (FSH) and luteinizing hormone (LH) levels. Incidence rate of IHH is 0.0005% in male, and 0.00001% in female. Even though R&D efforts related to the treatment have been going on for years in China, the ideal treatment for it had yet been available until the advent of MicroPort La Fenice® GnRH Infusion Pump.



This product stimulates hypophysis to excrete FSH/ LH by simulating pulse excretion of human gonadotropin-releasing hormone (GnRH) in order to make patients recover from abnormally physiological regulated function. Via treatment, patients can increase and maintain secondary sex characters, improve the deficiency of grown-up growth hormone

(GH) and bone mineral density (BMD), regain fertility, and reduce the risk of cardiovascular events.

Up until now, there have been two male IHH patients impregnated their partners and other two female patients have been fertilized successfully.

## MicroPort Hercules™ Systems Successfully Registered in Indonesia

Shanghai, August 14, 2012— MicroPort Hercules™ Systems, including Hercules™-B Bifurcated Stent-Graft System and Hercules™-T Thoracic Stent-Graft System, successfully registered in Indonesia. The registration is valid through December 31, 2015.

Hercules™-B Bifurcated Stent-Graft System is consisting of a proximal aortic trunk divided into two distinct lumens or sockets and one side connects to a smaller diameter leg (iliac) components. It is intended for the treatment of Abdominal Aortic Aneurysm (AAA).



Hercules™-T Thoracic Stent-Graft System is an endovascular stent graft and is used to repair fusiform aneurysms or saccular aneurysms/penetrating ulcers of the aorta in the chest. It is intended for the treatment of aortic aneurysm repair.



Up to now, Hercules™-B has been launched in many countries, including China, Venezuela, Philippines, Argentina, and Brazil. Hercules™-T also marched into markets like China, Thailand, Venezuela, Philippines, Argentina, Brazil, and Uruguay.

## MicroPort Established a New Subsidiary in Shanghai

MicroPort Scientific Corporation announced that MicroPort Endovascular (Shanghai) Co., Ltd, a new subsidiary of MicroPort, was established in Shanghai International Medical Zone (SIMZ). It was joint-ventured by MicroPort Medical (Shanghai) Co., Ltd and MicroPort Endovascular CHINA Corp. Limited and has obtained Enterprise Entity Business License on August 17, 2012. MicroPort Endovascular (Shanghai) Co., Ltd, primarily focuses on R&D, manufacturing, and marketing of aortic and peripheral vascular diagnostic devices as well as providing technical consultation and other related services.

## MicroPort Received SFDA Renewal for Disposable Endovascular Catheter Accessory System

Shanghai, July 10, 2012 — MicroPort announced renewal of MicroPort Disposable Endovascular Catheter Accessory System. It is primarily used in angioplasty and minimally-invasive operations and received SFDA renewal.

## MicroPort Firebird 2 Successfully Registered in Ecuador

Shanghai, July 9, 2012—MicroPort announced the registration for MicroPort Firebird2 Rapamycin-Eluting CoCr Coronary Stent System has been approved by Ecuador's FDA . It is the third product has successfully launched in the country after Firebird and Mustang. Currently, Firebird2 has successfully entered into eight countries includes Philippines, Thailand, Indonesia, Argentina, Brazil, Venezuela, Peru, and Ecuador.

## China Heart Congress 2012 Held in Beijing

Beijing, August 9-12, 2012—China Heart Congress (CHC) 2012 was held in Beijing. The theme of CHC2012 is “Healthy Heart, Better Life—Prevention, Translation, and Cooperation”. On August 11, MicroPort held a satellite symposium about the Firehawk in Shanghai. The following members presided over the meets.

During the symposium, Bo Xu, Director of Beijing Hu Wai Hospital presented the latest clinical progress of MicroPort Firehawk Rapamycin Target Eluting Coronary CoCr Stent System, and announced that the clinical study results will be published on TCT2012. Some invited doctors and physicians also offered case-based presentations on the Firehawk and highly praised it as “only one of its kind”.